Improvement of ACK1-targeted therapy efficacy in lung adenocarcinoma using chloroquine or bafilomycin A1

Improvement of ACK1-targeted therapy efficacy in lung adenocarcinoma using chloroquine or bafilomycin A1

Abstract Background Activated Cdc42-associated kinase 1 (ACK1) is a promising druggable target for cancer, but its inhibitors only showed moderate effects in clinical trials. The study aimed to investigate the underlying mechanisms and improve the antitumor efficacy of ACK1 inhibitors. Methods RNA-s...

Full description

Bibliographic Details
Main Authors: Jinhong Zhu, Kui Cao, Meng Zhao, Keru Ma, Xiangyu Jiang, Yuwen Bai, Xiaodong Ling, Jianqun Ma
Format: Article
Language:English
Published: BMC 2023-01-01
Series:Molecular Medicine
Subjects:
ACK1
LUAD
Chloroquine
Bafilomycin A1
AMPK
Prognosis
Online Access:https://doi.org/10.1186/s10020-023-00602-z

Internet

https://doi.org/10.1186/s10020-023-00602-z

Similar Items